Although chemotherapy, biological agents, and radiotherapy (RT) are cornerstones of the treatment of multiple myeloma (MM), the literature regarding the possible interactions of concurrent systemic treatment (CST) and RT is limited, and the optimal RT dose is still unclear.
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment
Guerini, Andrea Emanuele;Alongi, Filippo;Mataj, Eneida;Borghetti, Paolo;Triggiani, Luca;Pegurri, Ludovica;Pedretti, Sara;Bonù, Marco;Tomasini, Davide;Imbrescia, Jessica;Donofrio, Alessandra;Facheris, Giorgio;Singh, Navdeep;Tomasi, Cesare;Magrini, Stefano Maria;Spiazzi, Luigi;Buglione, Michela
2022-01-01
Abstract
Although chemotherapy, biological agents, and radiotherapy (RT) are cornerstones of the treatment of multiple myeloma (MM), the literature regarding the possible interactions of concurrent systemic treatment (CST) and RT is limited, and the optimal RT dose is still unclear.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
